The Patient First with Disruptive Technologies News Produkter Kongresser Service About us Jobba hos oss Kontakt Language: Resistance to anti-fungal drugs has become an important clinical problem, threatening the progress we have made in healthcare over the past 50 years. The last 20 years have seen very little change on how we diagnose fungal infections today. This has led to malpractice and increased medical costs. New strategies are needed to better treat and diagnose life-threatening fungal infections. The most threatening fungal pathogens are Candida, Aspergillus, Pneumocystis opch and Cryptococcus. OLM diagnostics is working to address the threat of drug resistance in fungi. Their research and development drive the company’s focus; to strengthen reputation as a trusted healthcare partner and to improve the outcome of patient health Clinicians can rely on the sensitivity and specificity of the tests to correctly identify true positives and true negatives. The tests are: AspDx: A series of tests that offer the ability to detect Aspergillus species to help with rapid and comprehensive diagnostics. The tests are both PCR and LFD based CandDx: A series of tests that offer the ability to detect Candida species (including C auris) to help the clinician with a more reliable diagnostic and treatment approach. The tests are both PCR and LFD based PneumDx: Possibility of detecting Pneumocystis jirovecii, a common cause of pneumonia and other respiratory infections. PCR based test. Copyright 2020 Diagen AS. All Rights Reserved

The Patient First with Disruptive Technologies News Produkter Kongresser Service About us Jobba hos oss Kontakt Language: Sorry, this entry is only available in Norsk, Swedish and Dansk. Copyright 2020 Diagen AS. All Rights Reserved

The Patient First with Disruptive Technologies News Produkter Kongresser Service About us Jobba hos oss Kontakt Language: Sorry, this entry is only available in Norwegian, Swedish and Danish. Copyright 2020 Diagen AS. All Rights Reserved

The Patient First with Disruptive Technologies Nyheter Produkter Kongresser Service Om Diagen Jobba hos oss Kontakt Language: Resistance testing for STDs MEET US E-MAIL +47 69294050 Copyright 2020 Diagen AS. All Rights Reserved

The Patient First with Disruptive Technologies News Produkter Kongresser Service About us Jobba hos oss Kontakt Language: Neonatal screening or screening of newborns means screening during the first few days of the child’s life to detect congenital metabolic defects and certain disorders that may hinder the child’s normal development. The disorders are not visible at birth, but have the potential to cause permanent neurological, cognitive, tactile and physical damages in the child. Early detection of these diseases enables early intervention to prevent long-term problems. Labsystems provides a wide range of screening instruments, including modular and fully automated NBS instruments, manual and automated equipment and reagents. Labsystems Diagnostics OY is one of the foremost in the world in terms of New Born Screening Technology. Click here to read more. Copyright 2020 Diagen AS. All Rights Reserved